Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIBF 1120 dose-ranging trial in idiopathic pulmonary fibrosis
2006-002875-42Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- May 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of nintedanib in idiopathic pulmonary fibrosis (IPF) (5 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Rate of decline in forced vital capacity. Started May 2007; status: completed.
02
Drugs
nintedanib
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on 2006-002875-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002875-42.